The authors concluded, “Pharmacotherapy is recommended in adults with dyslipidemia to reduce the risk of ASCVD events." The American Association of Clinical Endocrinology (AACE) has updated clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results